Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 22, 2026.

Presence of Late Gadolinium Enhancement by Cardiac Magnetic Resonance Among Patients With Suspected Cardiac Sarcoidosis Is Associated With Adverse Cardiovascular Prognosis

Edward Hulten, Vikram Agarwal, Michael Cahill and 8 more

Circulation: Cardiovascular Imaging · 2016 · Meta-analysis

doi:10.1161/circimaging.116.005001

Abstract

Background. Individuals with cardiac sarcoidosis have an increased risk of ventricular arrhythmia and death. Several small cohort studies have evaluated the ability of late gadolinium enhancement (LGE) by cardiac magnetic resonance imaging (MRI) to predict adverse cardiovascular events. However, studies have yielded inconsistent results, and some analyses were underpowered. Therefore, we sought to systematically review and perform meta-analysis of the prognostic value of cardiac MRI for patients with known or suspected cardiac sarcoidosis.

Methods and Results. We systematically searched for cohort studies of patients with known sarcoidosis with suspected cardiac involvement who underwent cardiac MRI with LGE with at least 12 months of either prospective or retrospective follow-up data regarding post-MRI adverse cardiovascular outcomes. We identified 7 studies of 694 subjects (mean age 53; 42% men). One hundred and ninety-nine patients (29%) were LGE positive. All-cause mortality occurred in 19 LGE-positive versus 17 LGE-negative subjects (annualized incidence, 3.1% versus 0.6%). The pooled relative risk was 3.38 (95% confidence interval, 1.07-10.7; P=0.04). Cardiovascular mortality occurred in 10 LGE-positive versus 2 LGE-negative subjects (annualized incidence, 1.9% versus 0.3%; relative risk 10.7 [95% confidence interval, 1.34–86.3]; P=0.03). Ventricular arrhythmia occurred in 41 LGE-positive versus 0 LGE-negative subjects (annualized incidence, 5.9% versus 0%; relative risk 19.5 [95% confidence interval, 2.68–143]; P=0.003). A combined end point of death or ventricular arrhythmia occurred in 64 LGE-positive versus 18 LGE-negative subjects (annualized incidence, 8.8% versus 0.6%; relative risk 6.20 [95% confidence interval, 2.47–15.6]; P<0.001). There was no significant heterogeneity for any outcomes.

Conclusions. LGE is associated with future cardiovascular death and ventricular arrhythmia among patients referred to MRI for known or suspected cardiac sarcoidosis.

References 22

  1. 1.

    Hulten E, Aslam S, Osborne M, Abbasi S, Bittencourt MS, Blankstein R. Cardiac sarcoidosis-state of the art review. Cardiovasc Diagn Ther. 2016;6:50-63.

    Not in our library10.3978/j.issn.2223-3652.2015.12.13

  2. 2.

    Blankstein R, Waller AH. Evaluation of Known or Suspected Cardiac Sarcoidosis. Circ Cardiovasc Imaging. 2016;9:e000867.

    Not in our library10.1161/circimaging.113.000867

  3. 3.

    Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, Crijns HJ. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683-1690.

    Not in our library10.1016/j.jacc.2005.01.047

  4. 4.

    Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120:1969-1977.

    Not in our library10.1161/circulationaha.109.851352

  5. 5.

    Murtagh G, Laffin LJ, Beshai JF, Maffessanti F, Bonham CA, Patel AV, Yu Z, Addetia K, Mor-Avi V, Moss JD, Hogarth DK, Sweiss NJ, Lang RM, Patel AR. Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction: Risk Stratification Using Cardiovascular Magnetic Resonance. Circ Cardiovasc Imaging. 2016;9:e003738.

    Not in our library10.1161/circimaging.115.003738

  6. 6.

    Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, Nothnagel D, Bültel H, Schumm J, Grün S, Ong P, Wagner A, Schneider S, Nassenstein K, Gawaz M, Sechtem U, Bruder O, Mahrholdt H. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501-511.

    Not in our library10.1016/j.jcmg.2012.10.021

  7. 7.

    Shafee MA, Fukuda K, Wakayama Y, Nakano M, Kondo M, Hasebe Y, Kawana A, Shimokawa H. Delayed enhancement on cardiac magnetic resonance imaging is a poor prognostic factor in patients with cardiac sarcoidosis. J Cardiol. 2012;60:448-453.

    Not in our library10.1016/j.jjcc.2012.08.002

  8. 8.

    Nadel J, Lancefield T, Voskoboinik A, Taylor AJ. Late gadolinium enhancement identified with cardiac magnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J Cardiovasc Imaging. 2015;16:634-641.

    Not in our library10.1093/ehjci/jeu294

  9. 9.

    Crawford T, Mueller G, Sarsam S, Prasitdumrong H, Chaiyen N, Gu X, Schuller J, Kron J, Nour KA, Cheng A, Ji SY, Feinstein S, Gupta S, Ilg K, Sinno M, Abu-Hashish S, Al-Mallah M, Sauer WH, Ellenbogen K, Morady F, Bogun F. Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2014;7:1109-1115.

    Not in our library10.1161/circep.113.000156

  10. 10.

    Nagai T, Kohsaka S, Okuda S, Anzai T, Asano K, Fukuda K. Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation. Chest. 2014;146:1064-1072.

    Not in our library10.1378/chest.14-0139

  11. 11.

    Schuller JL, Zipse M, Crawford T, Bogun F, Beshai J, Patel AR, Sweiss NJ, Nguyen DT, Aleong RG, Varosy PD, Weinberger HD, Sauer WH. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2012;23:925-929.

    Not in our library10.1111/j.1540-8167.2012.02350.x

  12. 12.

    Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC, Cooper JM. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm. 2012;9:884-891.

    Not in our library10.1016/j.hrthm.2012.02.010

  13. 13.

    Moher D, Liberati A, Tetzlaff J. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-9.

    Not in our library10.7326/0003-4819-151-4-200908180-00135

  14. 14.

    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.

    Not in our library10.1002/sim.1186

  15. 15.

    Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25:3443-3457.

    Not in our library10.1002/sim.2380

  16. 16.

    Beaule PE, Shea B, Abedlbary H, Ahmadzai N, Skidmore B, Mallick R, Hutton B, Bunting AC, Moran J, Ward R, Moher D. A protocol for a systematic review of the diagnostic accuracy of blood markers, synovial fluid, and tissue testing in periprosthetic joint infections (PJI). Syst Rev. 2015;4:148.

    Not in our library10.1186/s13643-015-0124-1

  17. 17.

    Hiraga H, Yuwai K, Hiroe M. Guidelines For Diagnosis Of Cardiac Sarcoidosis: Study Report On Diffuse Pulmonary Diseases. 1993;23-24.

    Not in our library

  18. 18.

    Hiraga H, Yuwai K, Hiroe M. Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis and Granulomatous Disorders. 2007;27:89-102.

    Not in our library

  19. 19.

    Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Cheriex EC, Gorgels AP, Crijns HJ. The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest. 2005;128:1629-1637.

    Not in our library10.1378/chest.128.3.1629

  20. 20.

    Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, Kazemian P, Kwong RY, Tokuda M, Skali H, Padera R, Hainer J, Stevenson WG, Dorbala S, Di Carli MF. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329-336.

    Not in our library10.1016/j.jacc.2013.09.022

  21. 21.

    Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, Judson MA, Kron J, Mehta D, Cosedis Nielsen J, Patel AR, Ohe T, Raatikainen P, Soejima K. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305-1323.

    Not in our library10.1016/j.hrthm.2014.03.043

  22. 22.

    Osborne MT, Hulten EA, Singh A, Waller AH, Bittencourt MS, Stewart GC, Hainer J, Murthy VL, Skali H, Dorbala S, Di Carli MF, Blankstein R. Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol. 2014;21:166-174.

    Not in our library10.1007/s12350-013-9828-6.23

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.